The American Society for Radiation Oncology issued a clinical guideline on the use of radiation therapy to treat adult patients with primary squamous cell carcinoma of the anal canal and anal margin.
B-cell acute lymphoblastic leukemia is a common type of ALL in adults.
A five-year study on subjects who had only the cancerous portion of their prostate glands destroyed shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function.
A study by University of Arizona Health Sciences researchers found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a synergistic treatment approach.
The phase III VERIFY trial, in which phlebotomy-dependent patients with polycythemia vera were randomized to treatment with either rusfertide (PTG-300) or placebo, as an add-on to standard of care treatment, met its primary endpoint of proportion of patients achieving response.
FDA approved Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (≥1).
The University of New England recently signed its first intellectual property license agreement with Satya Diagnostics—a company that recently received $100,000 in MaineHealth Bonfire Funding to help it achieve its goal of improving cancer detection and treatment in communities across the world.
The National Cancer Institute approved the following clinical research studies last month.
The House Republicans have narrowly pushed through a FY25 budget resolution, setting off a tangle of life-and-death sequelae for access to health insurance through Medicaid and Obamacare, and through a second-order effect, biomedical research.
On the evening of Feb. 15, when the dreaded letter of termination arrived, an NCI employee was just a few weeks away from job security—the end of the probationary period.
